These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

180 related items for PubMed ID: 27004402

  • 1. Oncogenic AKT1(E17K) mutation induces mammary hyperplasia but prevents HER2-driven tumorigenesis.
    Mancini ML, Lien EC, Toker A.
    Oncotarget; 2016 Apr 05; 7(14):17301-13. PubMed ID: 27004402
    [Abstract] [Full Text] [Related]

  • 2. Stat5 regulates the phosphatidylinositol 3-kinase/Akt1 pathway during mammary gland development and tumorigenesis.
    Schmidt JW, Wehde BL, Sakamoto K, Triplett AA, Anderson SM, Tsichlis PN, Leone G, Wagner KU.
    Mol Cell Biol; 2014 Apr 05; 34(7):1363-77. PubMed ID: 24469394
    [Abstract] [Full Text] [Related]

  • 3. Disruption of epithelial architecture caused by loss of PTEN or by oncogenic mutant p110α/PIK3CA but not by HER2 or mutant AKT1.
    Berglund FM, Weerasinghe NR, Davidson L, Lim JC, Eickholt BJ, Leslie NR.
    Oncogene; 2013 Sep 12; 32(37):4417-26. PubMed ID: 23085752
    [Abstract] [Full Text] [Related]

  • 4. Conditional loss of ErbB3 delays mammary gland hyperplasia induced by mutant PIK3CA without affecting mammary tumor latency, gene expression, or signaling.
    Young CD, Pfefferle AD, Owens P, Kuba MG, Rexer BN, Balko JM, Sánchez V, Cheng H, Perou CM, Zhao JJ, Cook RS, Arteaga CL.
    Cancer Res; 2013 Jul 01; 73(13):4075-85. PubMed ID: 23633485
    [Abstract] [Full Text] [Related]

  • 5. PI3K-p110α mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers.
    Wang Q, Liu P, Spangle JM, Von T, Roberts TM, Lin NU, Krop IE, Winer EP, Zhao JJ.
    Oncogene; 2016 Jul 07; 35(27):3607-12. PubMed ID: 26500061
    [Abstract] [Full Text] [Related]

  • 6. Activation of Akt1 accelerates carcinogen-induced tumorigenesis in mammary gland of virgin and post-lactating transgenic mice.
    Wu Y, Kim J, Elshimali Y, Sarkissyan M, Vadgama JV.
    BMC Cancer; 2014 Apr 17; 14():266. PubMed ID: 24742286
    [Abstract] [Full Text] [Related]

  • 7. Estrogen receptor beta growth-inhibitory effects are repressed through activation of MAPK and PI3K signalling in mammary epithelial and breast cancer cells.
    Cotrim CZ, Fabris V, Doria ML, Lindberg K, Gustafsson JÅ, Amado F, Lanari C, Helguero LA.
    Oncogene; 2013 May 09; 32(19):2390-402. PubMed ID: 22751110
    [Abstract] [Full Text] [Related]

  • 8. PKCtheta promotes c-Rel-driven mammary tumorigenesis in mice and humans by repressing estrogen receptor alpha synthesis.
    Belguise K, Sonenshein GE.
    J Clin Invest; 2007 Dec 09; 117(12):4009-21. PubMed ID: 18037997
    [Abstract] [Full Text] [Related]

  • 9. Mislocalization of the cell polarity protein scribble promotes mammary tumorigenesis and is associated with basal breast cancer.
    Feigin ME, Akshinthala SD, Araki K, Rosenberg AZ, Muthuswamy LB, Martin B, Lehmann BD, Berman HK, Pietenpol JA, Cardiff RD, Muthuswamy SK.
    Cancer Res; 2014 Jun 01; 74(11):3180-94. PubMed ID: 24662921
    [Abstract] [Full Text] [Related]

  • 10. PIK3CA and AKT1 mutations have distinct effects on sensitivity to targeted pathway inhibitors in an isogenic luminal breast cancer model system.
    Beaver JA, Gustin JP, Yi KH, Rajpurohit A, Thomas M, Gilbert SF, Rosen DM, Ho Park B, Lauring J.
    Clin Cancer Res; 2013 Oct 01; 19(19):5413-22. PubMed ID: 23888070
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Physiological levels of Pik3ca(H1047R) mutation in the mouse mammary gland results in ductal hyperplasia and formation of ERα-positive tumors.
    Tikoo A, Roh V, Montgomery KG, Ivetac I, Waring P, Pelzer R, Hare L, Shackleton M, Humbert P, Phillips WA.
    PLoS One; 2012 Oct 01; 7(5):e36924. PubMed ID: 22666336
    [Abstract] [Full Text] [Related]

  • 13. PIK3CA mutations and EGFR overexpression predict for lithium sensitivity in human breast epithelial cells.
    Higgins MJ, Beaver JA, Wong HY, Gustin JP, Lauring JD, Garay JP, Konishi H, Mohseni M, Wang GM, Cidado J, Jelovac D, Cosgrove DP, Tamaki A, Abukhdeir AM, Park BH.
    Cancer Biol Ther; 2011 Feb 01; 11(3):358-67. PubMed ID: 21124076
    [Abstract] [Full Text] [Related]

  • 14. PTEN deficiency in a luminal ErbB-2 mouse model results in dramatic acceleration of mammary tumorigenesis and metastasis.
    Schade B, Rao T, Dourdin N, Lesurf R, Hallett M, Cardiff RD, Muller WJ.
    J Biol Chem; 2009 Jul 10; 284(28):19018-26. PubMed ID: 19435886
    [Abstract] [Full Text] [Related]

  • 15. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors.
    Davies BR, Guan N, Logie A, Crafter C, Hanson L, Jacobs V, James N, Dudley P, Jacques K, Ladd B, D'Cruz CM, Zinda M, Lindemann J, Kodaira M, Tamura K, Jenkins EL.
    Mol Cancer Ther; 2015 Nov 10; 14(11):2441-51. PubMed ID: 26351323
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K/Akt/mTOR in estrogen receptor-positive, HER2-negative breast cancer.
    Araki K, Miyoshi Y.
    Breast Cancer; 2018 Jul 10; 25(4):392-401. PubMed ID: 29086897
    [Abstract] [Full Text] [Related]

  • 18. Landscape of Phosphatidylinositol-3-Kinase Pathway Alterations Across 19 784 Diverse Solid Tumors.
    Millis SZ, Ikeda S, Reddy S, Gatalica Z, Kurzrock R.
    JAMA Oncol; 2016 Dec 01; 2(12):1565-1573. PubMed ID: 27388585
    [Abstract] [Full Text] [Related]

  • 19. AKT1 (E17K) mutation profiling in breast cancer: prevalence, concurrent oncogenic alterations, and blood-based detection.
    Rudolph M, Anzeneder T, Schulz A, Beckmann G, Byrne AT, Jeffers M, Pena C, Politz O, Köchert K, Vonk R, Reischl J.
    BMC Cancer; 2016 Aug 11; 16():622. PubMed ID: 27515171
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.